Compounds > 13-oxo-9,11-octadecadienoic acid

Page last updated: 2024-09-04

13-oxo-9,11-octadecadienoic acid and 5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate

13-oxo-9,11-octadecadienoic acid has been researched along with 5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate in 1 studies

Compound Research Comparison

Studies (13-oxo-9,11-octadecadienoic acid)	Trials (13-oxo-9,11-octadecadienoic acid)	Recent Studies (post-2010) (13-oxo-9,11-octadecadienoic acid)	Studies (5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate)	Trials (5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate)	Recent Studies (post-2010) (5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate)
5	0	5	7	0	6

Protein Interaction Comparison

Protein	Taxonomy	13-oxo-9,11-octadecadienoic acid (IC50)	5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate (IC50)
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)		6.0256

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kishore, N; Kumar, P; Shanker, K; Verma, AK	1

Reviews

1 review(s) available for 13-oxo-9,11-octadecadienoic acid and 5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate

Article	Year
Human disorders associated with inflammation and the evolving role of natural products to overcome. European journal of medicinal chemistry, 2019, Oct-01, Volume: 179 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biological Products; Cardiovascular Diseases; Humans; Inflammation; Neoplasms; Skin Diseases	2019